Unlike other therapies, lomitapide does not work by trying to clear the high levels of cholesterol. It works by reducing the production and release of cholesterol from the liver and by reducing the absorption of cholesterol from the intestines following a meal. Specifically, lomitapide is an oral, selective inhibitor of microsomal triglyceride transfer protein (MTP) a protein necessary for the proper assembly and secretion of cholesterol containing molecules in the liver and the intestines. Inhibition of MTP reduces the levels of cholesterol containing molecules including cholesterol, LDL-C and triglycerides in the blood.

The U.S. Food & Drug Administration (FDA) granted authorisation for lomitapide under the trade name ‘Juxtapid’ in December 2012. Juxtapid® is indicated as:

An adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Please click here for Important Safety Information (US audiences only), including the Boxed Warning, and Full Prescribing

The European Commission (EC) granted authorisation for lomitapide under the trade name ‘Lojuxta’ in July 2013. Lojuxta® is indicated as:

An adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism) must be excluded.

See Lomitapideinfo.eu for further information (EU audiences only).

See the Summary of Product Characteristics (SPC) for further information (EU audiences only).

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Reporting forms and information can be found on the MHRA Yellow Card reporting site https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Amryt Pharmaceuticals DAC on:
Tel: +44 1604 549 952 or Freephone Number +800 4447 4447
E-mail: medinfo@amrytpharma.com

AMYT/ALL/007 August 2021